| Determinants of HIV-1 broadly neutralizing antibody induction P Rusert, RD Kouyos, C Kadelka, H Ebner, M Schanz, M Huber, DL Braun, ... Nature medicine 22 (11), 1260-1267, 2016 | 190 | 2016 |
| Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies P Rusert, A Krarup, C Magnus, OF Brandenberg, J Weber, AK Ehlert, ... Journal of Experimental Medicine 208 (7), 1419-1433, 2011 | 123 | 2011 |
| Estimating the stoichiometry of human immunodeficiency virus entry C Magnus, P Rusert, S Bonhoeffer, A Trkola, RR Regoes Journal of virology 83 (3), 1523-1531, 2009 | 123 | 2009 |
| Taming the BEAST—a community teaching material resource for BEAST 2 J Barido-Sottani, V Bošková, LD Plessis, D Kühnert, C Magnus, V Mitov, ... Systematic biology 67 (1), 170-174, 2018 | 120 | 2018 |
| Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry OF Brandenberg, C Magnus, P Rusert, RR Regoes, A Trkola PLoS pathogens 11 (1), e1004595, 2015 | 119 | 2015 |
| Myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome EM Flinn, CMC Busch, APH Wright Molecular and cellular biology 18 (10), 5961-5969, 1998 | 104 | 1998 |
| Modelling the course of an HIV infection: Insights from ecology and evolution S Alizon, C Magnus Viruses 4 (10), 1984-2013, 2012 | 99 | 2012 |
| Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain-and epitope-dependent L Reh, C Magnus, M Schanz, J Weber, T Uhr, P Rusert, A Trkola PLoS pathogens 11 (7), e1004966, 2015 | 98 | 2015 |
| Classic reaction kinetics can explain complex patterns of antibiotic action P Abel zur Wiesch, S Abel, S Gkotzis, P Ocampo, J Engelstädter, ... Science Translational Medicine 7 (287), 287ra73, 2015 | 92 | 2015 |
| The HIV-1 entry process: a stoichiometric view OF Brandenberg, C Magnus, RR Regoes, A Trkola Trends in microbiology 23 (12), 763-774, 2015 | 69 | 2015 |
| Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs CS Oberle, B Joos, P Rusert, NK Campbell, D Beauparlant, H Kuster, ... Retrovirology 13, 1-20, 2016 | 63 | 2016 |
| Profiling host ANP32A splicing landscapes to predict influenza A virus polymerase adaptation P Domingues, D Eletto, C Magnus, HL Turkington, S Schmutz, O Zagordi, ... Nature communications 10 (1), 3396, 2019 | 41 | 2019 |
| Estimating the stoichiometry of HIV neutralization C Magnus, RR Regoes PLoS computational biology 6 (3), e1000713, 2010 | 39 | 2010 |
| Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality D Beauparlant, P Rusert, C Magnus, C Kadelka, J Weber, T Uhr, ... PLoS pathogens 13 (3), e1006255, 2017 | 38 | 2017 |
| Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters OF Brandenberg, C Magnus, P Rusert, HF Günthard, RR Regoes, ... PLoS pathogens 13 (5), e1006313, 2017 | 32 | 2017 |
| The influence of phylodynamic model specifications on parameter estimates of the Zika virus epidemic V Boskova, T Stadler, C Magnus Virus evolution 4 (1), vex044, 2018 | 30 | 2018 |
| Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack WV Bonilla, N Kirchhammer, AF Marx, SM Kallert, MA Krzyzaniak, M Lu, ... Cell Reports Medicine 2 (3), 2021 | 27 | 2021 |
| Restricted occupancy models for neutralization of HIV virions and populations C Magnus, RR Regoes Journal of Theoretical Biology 283 (1), 192-202, 2011 | 26 | 2011 |
| Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain’s exceptional capacity for sequence variation OF Brandenberg, P Rusert, C Magnus, J Weber, J Böni, HF Günthard, ... Retrovirology 11, 1-22, 2014 | 24 | 2014 |
| IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization C Lanz, M Schotsaert, C Magnus, U Karakus, A Hunziker, ... Journal of Experimental Medicine 218 (6), e20200303, 2021 | 21 | 2021 |
